Para diabetes, opciones incluyen inhibidores SGLT2, inhibidores DPP-4, o insulina
However, based on the clinical trial criteria used in studies such as the Phase 2 trial published in the New England Journal of Medicine (2023), researchers have investigated its use in adults with: Obesity , defined as a body mass index (BMI) of 30 kg/m or above Overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as hypertension, dyslipidaemia, or obstructive sleep apnoea Type 2 diabetes , where improved glycaemic control alongside weight reduction is a treatment goal In clinical trials, participants were typically adults without a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
Altogether, this leads to weight loss an average of 15% to 21% body weight, per studies on semaglutide and tirzepatide (two popular GLP-1s) published in the The New England Journal of Medicine
Yes, for about 70% to 80% of people, retatrutide skin sensitivity improves significantly within two to four weeks